Completed OBSERVATIONAL NCT01077128

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

[E S] A Greek, Post-marketing, Observational Study of the quAlity of Life in Patients With Psoriasis Treated With Adalimumab - GOAL Study

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Psoriasis

Updated 7 times since 2017 Last updated: Feb 19, 2014 Started: Sep 30, 2009 Primary completion: Sep 30, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01077128, this observational or N/A phase trial focuses on Psoriasis and remains completed. Sponsored by AbbVie (prior sponsor, Abbott), it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Agrinio, Greece , Amaliáda, Greece , Argos, Greece , Argyroúpoli, Greece , Athens, Greece , Chania, Crete, Greece , Crete, Greece , Drama, Greece , Florina, Greece , Giannitsá, Greece and 23 more locations